Hemodialysis Vascular Grafts - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
The Hemodialysis Vascular Grafts Market size is estimated at USD 259.84 million in 2024, and is expected to reach USD 329.41 million by 2029, growing at a CAGR of 4.86% during the forecast period (2024-2029).
Factors such as the increasing prevalence of end-stage renal disease (ESRD) and the rising geriatric population are expected to drive the market growth. For instance, as per the article published in the journal Kidney International Supplements in April 2022, chronic kidney disease (CKD) has affected over 10% of the general population worldwide to date. CKD accentuates the demand for hemodialysis since hemodialysis is one of the major options for treating advanced kidney failure and helping the kidneys from failure.
An increase in the geriatric population is expected to support the market growth since these age groups are more prone to acquiring chronic diseases and demand the adoption of hemodialysis vascular grafts. For instance, according to the October 2023 update by the World Health Organization (WHO), the estimated geriatric population in the European region is expected to exceed those under 15 in 2024. The number of functional nephrons decreases with aging, and the remaining nephrons may become less efficient. These age-related changes reduce the ability to filter waste products and maintain fluid and electrolyte balance. This led to increased demand for hemodialysis vascular grafts, driving market growth.
Also, various clinical trials for developing hemodialysis vascular grafts are expected to drive market growth. For instance, in April 2023, Xeltis presented six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society in Porto, Portugal. aXess is a vascular access graft intended for chronic kidney disease (CKD) patients requiring hemodialysis. Thus, an increase in positive outcomes from the clinical trial is expected to increase the chance for market approval and availability of hemodialysis vascular grafts, thereby driving market growth.
Hence, owing to the high prevalence of CKD in the geriatric population and positive outcomes from clinical trials regarding vascular grafts, the hemodialysis vascular grafts market is anticipated to grow during the forecast period. However, high cost and alternative treatment options are expected to restrain the growth of the global market during the forecast period.
Hemodialysis Vascular Grafts Market Trends
The Polytetrafluoroethylene Segment is Expected to Witness Significant Growth During the Forecast Period
The growth of the polytetrafluoroethylene segment is attributed to several factors, such as the increasing prevalence of end-stage renal disease, the growing aging population, the clinical advantages of polytetrafluoroethylene, and technological advancements. For instance, according to an article published by Frontiers in Nephrology in October 2022, the most frequently used synthetic graft is made of polytetrafluorethylene (PTFE), a fluorocarbon polymer. The stretch expanded (ePTFE) form is preferred based on a one-year cumulative patency rate of 59% and 29% for ePTFE. Its availability, ease of handling, biocompatibility, long-term stability, rapid use, and significant decrease in cost made the PTFE graft a first choice for surgeons. Thus, an increased preference and advantage of PTFE graft over others is expected to increase its demand, leading to segmental growth.
Also, advancements and new technologies of vascular grafts, with the help of polytetrafluoroethylene, are expected to fuel the segment's growth. For instance, as per the article published in February 2024 in Polymer Engineering & Science, the researchers developed highly compliant expanded polytetrafluoroethylene (ePTFE) grafts without requiring supplementary additives or inherent material alterations. The advanced expanded polytetrafluoroethylene exhibited an elastic strain capacity similar to native vasculature. Thus, such advancements in polytetrafluoroethylene will likely drive the segment growth during the forecast period.
Also, the companies are actively involved in new product launch developments, acquisitions, and collaborations to expand their footprint, which is expected to drive market growth. For instance, in August 2022, W. L. Gore & Associates Inc. reported the acquisition of InnAVasc Medical Inc. for patients with end-stage renal disease who utilize graft circuits for dialysis treatment.
Thus, owing to the benefits offered by polytetrafluoroethylene in vascular grafts, the demand for this material will likely rise during the forecast period, leading to segment growth.
Asia-Pacific is Expected to Hold a Significant Growth in the Hemodialysis Vascular Grafts Market
Asia-Pacific is expected to witness high growth in the hemodialysis vascular grafts market, attributed to the high burden of chronic kidney disease, high disposable income, and the high acceptance rate of technologically improved products. For instance, according to an article published by BMJ Global Health in January 2023, chronic kidney disease is a major, growing health concern in Asia, particularly in China and India, affecting a substantial proportion of its population. As per the above source, the large number of people with chronic kidney disease and the considerable number with advanced chronic kidney disease show the need for urgent collaborative action in Asia to prevent and manage chronic kidney disease and its complications. Thus, with an increased need for collaborative action in Asia for chronic kidney disease, the demand for hemodialysis vascular grafts increased, thereby driving regional growth.
Additionally, many dialysis centers in this region and a rise in patients with chronic renal and kidney diseases are expected to boost the market growth. For instance, according to a report published by the national health portal of the Indian government in July 2022, it was estimated that every year, about 2.2 lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 crore dialysis. Similarly, in April 2023, the Albanese government opened a few new renal dialysis units in six remote locations so patients with severe kidney disease could receive life-saving treatment closer to their communities. The high burden of patients with end-stage renal disease coupled with an increase in dialysis centers is expected to increase the demand for hemodialysis vascular grafts, thereby driving the market growth in the region.
Hence, owing to the high number of kidney disease cases and the rise in dialysis unit launches, the market is expected to witness notable growth in the country during the forecast period.
Hemodialysis Vascular Grafts Industry Overview
The hemodialysis vascular grafts market is semi-consolidated due to the presence of companies operating globally and regionally. Many players in this market are trying to expand their product portfolios to grow their regional presence. While few companies are entering the market through acquisitions, top companies are expanding their growth by acquiring other companies. The competitive landscape includes analyzing companies, including W. L. Gore & Associates Inc., Vascudyne Inc., LeMaitre, Getinge AB, and CryoLife Inc.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
Factors such as the increasing prevalence of end-stage renal disease (ESRD) and the rising geriatric population are expected to drive the market growth. For instance, as per the article published in the journal Kidney International Supplements in April 2022, chronic kidney disease (CKD) has affected over 10% of the general population worldwide to date. CKD accentuates the demand for hemodialysis since hemodialysis is one of the major options for treating advanced kidney failure and helping the kidneys from failure.
An increase in the geriatric population is expected to support the market growth since these age groups are more prone to acquiring chronic diseases and demand the adoption of hemodialysis vascular grafts. For instance, according to the October 2023 update by the World Health Organization (WHO), the estimated geriatric population in the European region is expected to exceed those under 15 in 2024. The number of functional nephrons decreases with aging, and the remaining nephrons may become less efficient. These age-related changes reduce the ability to filter waste products and maintain fluid and electrolyte balance. This led to increased demand for hemodialysis vascular grafts, driving market growth.
Also, various clinical trials for developing hemodialysis vascular grafts are expected to drive market growth. For instance, in April 2023, Xeltis presented six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society in Porto, Portugal. aXess is a vascular access graft intended for chronic kidney disease (CKD) patients requiring hemodialysis. Thus, an increase in positive outcomes from the clinical trial is expected to increase the chance for market approval and availability of hemodialysis vascular grafts, thereby driving market growth.
Hence, owing to the high prevalence of CKD in the geriatric population and positive outcomes from clinical trials regarding vascular grafts, the hemodialysis vascular grafts market is anticipated to grow during the forecast period. However, high cost and alternative treatment options are expected to restrain the growth of the global market during the forecast period.
Hemodialysis Vascular Grafts Market Trends
The Polytetrafluoroethylene Segment is Expected to Witness Significant Growth During the Forecast Period
The growth of the polytetrafluoroethylene segment is attributed to several factors, such as the increasing prevalence of end-stage renal disease, the growing aging population, the clinical advantages of polytetrafluoroethylene, and technological advancements. For instance, according to an article published by Frontiers in Nephrology in October 2022, the most frequently used synthetic graft is made of polytetrafluorethylene (PTFE), a fluorocarbon polymer. The stretch expanded (ePTFE) form is preferred based on a one-year cumulative patency rate of 59% and 29% for ePTFE. Its availability, ease of handling, biocompatibility, long-term stability, rapid use, and significant decrease in cost made the PTFE graft a first choice for surgeons. Thus, an increased preference and advantage of PTFE graft over others is expected to increase its demand, leading to segmental growth.
Also, advancements and new technologies of vascular grafts, with the help of polytetrafluoroethylene, are expected to fuel the segment's growth. For instance, as per the article published in February 2024 in Polymer Engineering & Science, the researchers developed highly compliant expanded polytetrafluoroethylene (ePTFE) grafts without requiring supplementary additives or inherent material alterations. The advanced expanded polytetrafluoroethylene exhibited an elastic strain capacity similar to native vasculature. Thus, such advancements in polytetrafluoroethylene will likely drive the segment growth during the forecast period.
Also, the companies are actively involved in new product launch developments, acquisitions, and collaborations to expand their footprint, which is expected to drive market growth. For instance, in August 2022, W. L. Gore & Associates Inc. reported the acquisition of InnAVasc Medical Inc. for patients with end-stage renal disease who utilize graft circuits for dialysis treatment.
Thus, owing to the benefits offered by polytetrafluoroethylene in vascular grafts, the demand for this material will likely rise during the forecast period, leading to segment growth.
Asia-Pacific is Expected to Hold a Significant Growth in the Hemodialysis Vascular Grafts Market
Asia-Pacific is expected to witness high growth in the hemodialysis vascular grafts market, attributed to the high burden of chronic kidney disease, high disposable income, and the high acceptance rate of technologically improved products. For instance, according to an article published by BMJ Global Health in January 2023, chronic kidney disease is a major, growing health concern in Asia, particularly in China and India, affecting a substantial proportion of its population. As per the above source, the large number of people with chronic kidney disease and the considerable number with advanced chronic kidney disease show the need for urgent collaborative action in Asia to prevent and manage chronic kidney disease and its complications. Thus, with an increased need for collaborative action in Asia for chronic kidney disease, the demand for hemodialysis vascular grafts increased, thereby driving regional growth.
Additionally, many dialysis centers in this region and a rise in patients with chronic renal and kidney diseases are expected to boost the market growth. For instance, according to a report published by the national health portal of the Indian government in July 2022, it was estimated that every year, about 2.2 lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 crore dialysis. Similarly, in April 2023, the Albanese government opened a few new renal dialysis units in six remote locations so patients with severe kidney disease could receive life-saving treatment closer to their communities. The high burden of patients with end-stage renal disease coupled with an increase in dialysis centers is expected to increase the demand for hemodialysis vascular grafts, thereby driving the market growth in the region.
Hence, owing to the high number of kidney disease cases and the rise in dialysis unit launches, the market is expected to witness notable growth in the country during the forecast period.
Hemodialysis Vascular Grafts Industry Overview
The hemodialysis vascular grafts market is semi-consolidated due to the presence of companies operating globally and regionally. Many players in this market are trying to expand their product portfolios to grow their regional presence. While few companies are entering the market through acquisitions, top companies are expanding their growth by acquiring other companies. The competitive landscape includes analyzing companies, including W. L. Gore & Associates Inc., Vascudyne Inc., LeMaitre, Getinge AB, and CryoLife Inc.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of End-Stage Renal Disease (ESRD)
4.2.2 Rising Geriatric Population
4.3 Market Restraints
4.3.1 High Cost and Alternative Treatment Options
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE - USD)
5.1 By Raw Material
5.1.1 Polyester
5.1.2 Polytetrafluoroethylene
5.1.3 Polyurethane
5.1.4 Biological Materials
5.1.4.1 Human Saphenous & Umbilical Veins
5.1.4.2 Tissue Engineered Materials
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 W. L. Gore & Associates Inc.
6.1.2 Vascudyne Inc.
6.1.3 LeMaitre
6.1.4 Getinge AB
6.1.5 ParaGen Technologies
6.1.6 InnAVasc Medical Inc.
6.1.7 CryoLife Inc.
6.1.8 Merit Medical Systems
6.1.9 BIOVIC Sdn Bhd
6.1.10 Becton, Dickinson and Company
6.1.11 Laminate Medical Technologies
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of End-Stage Renal Disease (ESRD)
4.2.2 Rising Geriatric Population
4.3 Market Restraints
4.3.1 High Cost and Alternative Treatment Options
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE - USD)
5.1 By Raw Material
5.1.1 Polyester
5.1.2 Polytetrafluoroethylene
5.1.3 Polyurethane
5.1.4 Biological Materials
5.1.4.1 Human Saphenous & Umbilical Veins
5.1.4.2 Tissue Engineered Materials
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 W. L. Gore & Associates Inc.
6.1.2 Vascudyne Inc.
6.1.3 LeMaitre
6.1.4 Getinge AB
6.1.5 ParaGen Technologies
6.1.6 InnAVasc Medical Inc.
6.1.7 CryoLife Inc.
6.1.8 Merit Medical Systems
6.1.9 BIOVIC Sdn Bhd
6.1.10 Becton, Dickinson and Company
6.1.11 Laminate Medical Technologies
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
